Protara Therapeutics (TARA) Enterprise Value (2013 - 2026)

Protara Therapeutics' Enterprise Value history runs 14 years deep, the most recent figure standing at -$135.8 million for Q1 2026.

• In Q1 2026, Enterprise Value fell 9.19% year-over-year to -$135.8 million; the TTM figure through Mar 2026 stood at -$135.8 million (down 9.19% YoY), while the FY2025 annual figure was -$155.6 million, up 8.65% from the prior year.
• Enterprise Value was -$135.8 million for Q1 2026 at Protara Therapeutics, up from -$155.6 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$55.2 million in Q1 2024 to a low of -$170.3 million in Q4 2024.
• Historically, Enterprise Value has averaged -$102.4 million across 5 years, with a median of -$89.6 million in 2024.
• The sharpest annual moves came in 2022 and 2024: Enterprise Value jumped 52.48% in 2022, then tumbled 159.67% in 2024.
• A 5-year view of Enterprise Value shows it stood at -$84.4 million in 2022, then climbed by 22.27% to -$65.6 million in 2023, then sank by 159.67% to -$170.3 million in 2024, then advanced by 8.65% to -$155.6 million in 2025, then gained by 12.71% to -$135.8 million in 2026.
• The last three Enterprise Value figures came in at -$135.8 million (Q1 2026), -$155.6 million (Q4 2025), and -$132.7 million (Q3 2025), per Business Quant data.